A US Food and Drug Administration (FDA) expert panel will meet Tuesday to consider whether to recommend approval of an investigational midomafetamine (MDMA) capsule in combination with psychological intervention for the treatment of posttraumatic stress disorder (PTSD). But as the drug manufacturer, Lykos Therapeutics, inches closer to a final decision on its new drug application …
